Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Dose-Blind, Phase 3 Long-Term Extension Study to Evaluate Continuous Safety and Efficacy of Litifilimab (BIIB059) in Adult Participants With Active Systemic Lupus Erythematosus

NCT05352919 is registered in ClinicalTrials.gov with Biogen as lead sponsor.

NCT NCT05352919
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05352919 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Dose-Blind, Phase 3 Long-Term Extension Study to Evaluate Continuous Safety and Efficacy of Litifilimab (BIIB059) in Adult Participants With Active Systemic Lupus Erythematosus
Lead sponsor
Biogen
Phase
Phase 3
Overall status
Enrolling by invitation
Start date
June 10, 2022
Completion date
May 3, 2032
Enrollment
864 (estimated)
Sites
214

Conditions

As the registry lists them; a condition with its own page is linked.

systemic lupus erythematosus (sle)